EU/3/20/2289: Orphan designation for the treatment of bullous pemphigoid

Nomacopan

Overview

On 26 June 2020, orphan designation EU/3/20/2289 was granted by the European Commission to Akari Malta Limited, Malta, for Nomacopan (also known as Coversin) for the treatment of bullous pemphigoid.

The sponsor’s address was updated in January 2022.

Key facts

Active substance
Nomacopan
Intented use
Treatment of bullous pemphigoid
Orphan designation status
Positive
EU designation number
EU/3/20/2289
Date of designation
26/06/2020
Sponsor

Akari Malta Limited, Malta
189 Marina Suites
Suite 10
Marina Street
Pieta
PTA 9041
Malta
Tel: +356 2065 0510
E-mail: info@akaritx.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating